Home » Topics » BioWorld Science, Dermatologic

BioWorld Science, Dermatologic
RSS

Phase II study finds IL-2 fusion protein effective but toxic in patients with psoriasis

July 27, 1998

Antipsoriatic dihydrofolate reductase inhibitors available for licensing from BTG

July 22, 1998

Altana offer to license Solarase accepted by Hyal

July 21, 1998

Celgene cleared to market Thalomid in U.S.

July 20, 1998

First demonstration of efficacy for PDT in treating autoimmune disorders

July 17, 1998

Mylan announces copromotion agreement

July 15, 1998

Phase III trial of new foam formulation of clobetasol initiated

July 14, 1998

Dermatological agents in development at Galderma

July 10, 1998

Phase III study shows efficacy of becaplermin treatment for diabetic neuropathic ulcers

July 8, 1998

Dusa submits NDA for Levulan PDT of actinic keratoses

July 6, 1998

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026